Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
May 01, 2024 08:00 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
April 29, 2024 07:00 ET
|
Prime Medicine, Inc.
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
April 23, 2024 08:00 ET
|
Prime Medicine, Inc.
-- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on track to enter...
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
March 01, 2024 08:00 ET
|
Prime Medicine, Inc.
-- Maturing into clinical-stage company; on-track to file IND application or CTA for PM359 in 1H 2024, with initial data expected in 2025 -- -- Progressing broader portfolio across core areas of...
Prime Medicine to Participate in Upcoming Investor Conferences
February 28, 2024 08:00 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 20, 2024 16:01 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine Announces Pricing of Upsized Public Offering
February 14, 2024 23:50 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine Announces Proposed Public Offering of Common Stock
February 14, 2024 16:05 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024 08:00 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
January 25, 2024 08:00 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...